Preclinical Research for Breast Cancer

Each subtype exhibits distinct prognosis and treatment strategies, encompassing surgery, radiation therapy, chemotherapy, and endocrine therapy. Alfa Cytology offers preclinical research services focusing on breast cancer investigations, delivering comprehensive solutions for your drug development endeavors.

Overview of Preclinical Research for Breast Cancer

Preclinical research plays a crucial role in the development of breast cancer therapeutics. Studies have reported the anticancer properties of SGLT2 inhibitors in breast cancer treatment. Through preclinical investigations, they discovered that SGLT2 inhibitors can induce apoptosis in breast cancer cells, potentially aiding in tumor reduction. The inhibitors have demonstrated the potential to enhance the effectiveness of chemotherapy or targeted therapy in breast cancer treatment.

Fig. 1. Exploring the SGLT2 inhibitors in breast cancer treatment in pre-clinical studies. (Naeimzadeh Y, et al., 2024)

Our Services

At Alfa Cytology, we offer cutting-edge preclinical research services specifically designed for drug development in breast cancer. We are your trusted partner, tailoring solutions to meet the requirements and complexities of each trial. Our comprehensive preclinical services include, but are not limited to, the assessment of the safety, efficacy, pharmacokinetics (PK), and toxicology of antiviral agents, drugs, antibodies, and vaccines.

Contact Us

Alfa Cytology provides the highest quality services for complex preclinical studies in large models. Our experts provide comprehensive data analysis and reporting, offering valuable insights for the development of breast cancer drugs. Please contact us to discuss your project requirements.